Research & Development
OliX Pharmaceuticals granted FDA approval to develop RNAi therapeutic for AMD
3 August 2022 -

OliX Pharmaceuticals Inc (KOSDAQ:226950), a pharmaceutical company based in South Korea, said on Wednesday that the US Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application to develop its RNAi therapeutic OLX10212 for the treatment of age-related macular degeneration (AMD).

OLX10212 targets inflammation pathways that play a key role in the development of geographic atrophy (GA) and neovascular AMD. The primary objective of the phase 1 study is to evaluate the safety and tolerability of OLX10212 in patients with AMD.

With the FDA approval of the IND application for OLX10212, OliX has initiated clinical trials for two investigational therapeutic programmes in the US. In June 2022 the company completed patient enrolment for the Phase 2a clinical trial of OLX10010, for the treatment of hypertrophic scarring.

Login
Username:

Password: